WIXOM, Mich. - Future Pak, LLC has made a bid to acquire Theratechnologies Inc. (NASDAQ: THTX), a pharmaceutical company currently valued at $59.08 million in market capitalization, with a ...

Additionally, Theratechnologies has presented promising results for ibalizumab, used in combination antiretroviral therapy, for patients with multidrug-resistant HIV. The PROMISE-US study, presented ...

Since 2018, three medications have been approved by the FDA for use in heavily treatment-experienced or treatment-resistant HIV: ibalizumab, fostemsavir and lenacapavir.

Bupropion, used to treat major depressive disorder; ibalizumab, for patients with multi-drug-resistant HIV; and sotalol, to treat a life-threatening heart rhythm problem: those are just some of ...

BUFFALO, N.Y. — Luis De Jesús Báez, PhD, assistant professor of chemistry at the University at Buffalo, has been selected as a 2025 Young Observer by the U.S. National Committee for the International ...

The company successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV and continues to pioneer long-acting biologics and antibody-drug ...

(MENAFN- GlobeNewsWire - Nasdaq) Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV ...

The first in-person meeting of the IUPAC Science Board was held on 16 January 2025, hosted by the Royal Society of Chemistry at its historic Burlington House London home, to discuss the scientific ...

Theratechnologies (THTX) announced that the production of Egrifta SV has resumed following a voluntary shutdown of the company’s contract manufacturer’s facility to address observations from ...

Review the side-effects of Ibalizumab-uiyk as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication.

Another poster reports on the study design and baseline characteristics of the PROMISE-US trial, an observational, real-world study of ibalizumab, a CD4-directed post-attachment inhibitor of HIV, in ...